We’re excited to announce that a new Phase III clinical trial is now open for recruitment. This study is focused on patients with advanced gastrointestinal stromal tumors (GIST) who have previously been treated with Imatinib.
Study Overview:
- Objective: The trial aims to compare the effectiveness of two treatments: DCC-2618 and Sunitinib.
- Sponsor: This study is sponsored by Deciphera Pharmaceuticals LLC in collaboration with Maisonneuve-Rosemont Hospital (HMR).
- Status: The study is currently active and open for recruitment.
This important research seeks to provide valuable insights into new treatment options for advanced GIST, a condition that can be challenging to manage. If you or someone you know is eligible and interested in participating, please reach out for more details.
Stay tuned for updates on this promising study and its progress!
